Lyra Therapeutics Faces Delisting from Nasdaq
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 06 2026
0mins
On February 2, Lyra Therapeutics received a letter from the Listing Qualifications Department of The Nasdaq Stock Market notifying the company that Nasdaq has determined to delist the company's common stock from The Nasdaq Stock Market. The company has requested a hearing before a Nasdaq Hearings Panel to appeal Nasdaq's determination.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
